As the industry moves toward biologics and cold-chain-dependent gene therapies, expect USP to expand <1136> further to address real-time monitoring, digital data integrity (aligned with <1058>), and risk-based stability approaches.
Disclaimer: This article is for informational purposes only and does not constitute legal or regulatory advice. Always consult the official USP–NF for the most current version of general chapters. usp -38 general chapter 1136-
In the context of USP-38, traceability is paramount. If a recall occurs, the lot number on a single-unit package allows the facility to identify and remove affected stock quickly. Without adherence to 1136 labeling standards, tracing medications in a decentralized hospital dispensing cabinet (like a Pyxis or Omnicell) becomes a nightmare. In the context of USP-38, traceability is paramount
In the world of sterile pharmaceutical manufacturing, the naked eye is often the least reliable tool. For decades, the United States Pharmacopeia (USP) has provided rigorous standards to protect patients from subvisible and visible particulate contamination in parenteral drug products. While most industry professionals are familiar with USP <787> and USP <788> (Subvisible Particulate Matter in Therapeutic Protein Injections and Injections), a less discussed but equally critical chapter has emerged as a cornerstone of modern contamination control: . In the world of sterile pharmaceutical manufacturing, the
Root cause analysis guided by finds:
Must meet the chemical resistance and light transmission requirements of USP Containers—Glass .
| Feature | USP <659> | USP <1136> | |---------|-----------|------------| | Focus | Container/closure physical testing | Operational storage & labeling | | Audience | Packaging engineers | QA, logistics, pharmacy | | Excursion handling | Not addressed | Yes – time/temperature budgets | | Light protection testing | Quantitative (transmission %) | Qualitative implementation guide |